Posted on

naturewell inc cbd

Among individuals with the full mutation (i.e., >200 CGG repeats), symptoms of FXS vary by age and sex, but often include anxiety (80%), social avoidance (80%), stereotyped behaviors (80%), attention-deficit/hyperactivity disorder (70%), autism spectrum disorders (60%), intellectual disability (85% of males and 25% of females), aggression (40%), disrupted sleep patterns (40%), and epilepsy (16%), as well as macroorchidism (90% of adults), prominent ears (60%), long faces (60%), soft skin (50%), and hyperextensible joints (60% of children). 9–11 Traditional allopathic treatment of these patients may involve medications to address issues with sleep (melatonin and clonidine), anxiety (selective serotonin reuptake inhibitors and benzodiazepines), hyperactivity and deficits in attention (psychostimulants), and seizures (carbamazepine, valproic acid, and lamotrigine). 12 Yet, for many patients with FXS, the aforementioned pharmacotherapies, when used alone or in combination, have suboptimal efficacy and tolerability, 11–13 suggesting a persistent unmet medical need for novel, interventional treatment approaches for patients with FXS. Because the clinical abnormalities in these patients (and most recently in children with autism spectrum disorder 14 ) have been linked, at least in part, with dysregulation of the endocannabinoid system, we briefly review recent research characterizing the involvement of the endocannabinoid system in FXS and present the cases of three individuals (one child and two adults) with FXS who experienced functional benefit after treatment with cannabidiol (CBD)-enriched (CBD+) preparations.

Abstract

3 Department of Pediatrics, MIND Institute, University of California Davis Medical Center, Sacramento, California.

Marcel Bonn-Miller

At the 4-month follow-up visit, the patient’s weight had increased to the 15th percentile, while his length remained at the 50th percentile. Developmental progress included improved fine and gross motor skills, decreased repetitive rocking, improved social interest/engagement, improved vocalizations, and decreased hyperactivity. The patient began a regimen of sertraline (2.5 mg per day) due to preliminary evidence of improved language and development in young children with FXS treated with sertraline. 37,38 Subsequent follow-up visits (at 21 and 27 months of age) showed continued improvement in language and developmental skills. The patient started walking and self-feeding independently, exhibited more frequent and varied vocalizations, fewer repetitive and motor behaviors, fewer sensory sensitivities (e.g., tolerated noise and lights of fireworks), and more frequent initiation of joint attention with pointing. Weight increased to the 25th percentile. He continued using CBD+ solution and remained in a strong early intervention program: 1 h per week of occupational, speech, and physical therapy; 6 h per week of Early Start Denver Model behavioral therapy and applied behavioral analysis.

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. ยงยง 1001 and 1030).

More Information

Reference ID: 0.5dfd733e.1642006436.94cb8e2f

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact [email protected]

Internet Security Policy

Please declare your traffic by updating your user agent to include company specific information.

To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Your request has been identified as part of a network of automated tools outside of the acceptable policy and will be managed until action is taken to declare your traffic.